

Press release

Change in the number of shares and votes in Camurus AB

Lund, Sweden — 29 June 2018 — Camurus AB (publ) (Nasdaq Stockholm: CAMX) today announced that the company's total number of shares as per 29 June 2018 amounts to 38,381,486 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of 1,100,000 shares to Swedish and international investors announced on 29 June 2018.

About Camurus

Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit www.camurus.com.

For more information

Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Rein Piir, Investor Relations
Tel. +46 (0)70 853 72 92
ir@camurus.com

This information is information that Camurus AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 4.30 pm CET on 29 June 2018.